SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Cellectis S.A. (CMVLF) .
Criteria proven by this page:
- VALUE (0/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.
Overall SharesGrow Score: 34/100 with 1/7 criteria passed.
SharesGrow 7-Criteria Score
✗
HEALTH
33/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — CMVLF
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio4.07
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-0.70
Book Value / Share$0.00
Revenue / Share$0.76
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$-1.78 |
$42.58M |
$-63.92M |
-150.1% |
| 2017 |
$-2.78 |
$25.19M |
$-99.37M |
-394.5% |
| 2018 |
$-1.93 |
$12.73M |
$-78.69M |
-618.1% |
| 2019 |
$-2.41 |
$15.19M |
$-102.09M |
-672.1% |
| 2020 |
$-1.91 |
$73.95M |
$-81.07M |
-109.6% |
| 2021 |
$-1.81 |
$73.95M |
$-81.07M |
-109.6% |
| 2022 |
$-2.33 |
$19.17M |
$-106.14M |
-553.6% |
| 2023 |
$-1.77 |
$755K |
$-103.17M |
-13665.4% |
| 2024 |
$-0.41 |
$41.51M |
$-36.76M |
-88.6% |
| 2025 |
$-0.70 |
$75.92M |
$-70.34M |
-92.7% |
